Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

EVAXBullishIndustry Newsnews

High materiality7/10

EVAX to Present Phase 2 EVX-01 Biomarker Data at SITC 2026

Nov 3, 2026, 9:22 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Conference-driven catalysts frequently move biotech stocks. A positive signal from biomarker data showing systemic immunomodulation and pembrolizumab synergy could lift EVAX sentiment, attract partners, and trigger a short-term rally, though actual data readouts are required for sustained moves.

AI summary

What happened, with direct paths to the underlying reporting

Evaxion will present new biomarker data from its EVX-01 phase 2 cancer vaccine at SITC 2026 in Phoenix, focusing on systemic immunomodulatory effects when combined with pembrolizumab. If the data show meaningful non-targeted immune changes, it could expand EVX-01's potential and attract partnerships or increased investor interest ahead of subsequent trials.

Evaxion to present EVX-01 phase 2 biomarker data at SITC 2026.
Data includes broad systemic immunomodulatory effects of EVX-01 plus pembrolizumab.
Presentation at SITC includes oral and poster sessions.
Event scheduled in Phoenix, AZ, November 4–8, 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.